MX2024000986A - Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. - Google Patents

Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.

Info

Publication number
MX2024000986A
MX2024000986A MX2024000986A MX2024000986A MX2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A MX 2024000986 A MX2024000986 A MX 2024000986A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
treatment
coronaviral
related diseases
Prior art date
Application number
MX2024000986A
Other languages
English (en)
Spanish (es)
Inventor
Jun Yuan
Lei Shi
Julien Papillon
Bo Liu
Heinz Ernst Moser
Sajan Joseph
Jr Thomas Martin Kirrane
Matthew James Hesse
Denghui Bao
Fengfeng Guo
Viktor Hornak
Haiyao Lin
yanan Miao
Yang Qu
Teng Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2024000986A publication Critical patent/MX2024000986A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024000986A 2021-07-22 2022-07-20 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. MX2024000986A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163224793P 2021-07-22 2021-07-22
US202163289009P 2021-12-13 2021-12-13
PCT/IB2022/056712 WO2023002409A1 (en) 2021-07-22 2022-07-20 Compounds and compositions for the treatment of coronaviral related diseases

Publications (1)

Publication Number Publication Date
MX2024000986A true MX2024000986A (es) 2024-02-12

Family

ID=82742919

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000986A MX2024000986A (es) 2021-07-22 2022-07-20 Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.

Country Status (11)

Country Link
US (1) US20250092016A1 (https=)
EP (1) EP4373814A1 (https=)
JP (1) JP2024527424A (https=)
KR (1) KR20240038996A (https=)
AU (1) AU2022315058A1 (https=)
CA (1) CA3226758A1 (https=)
MX (1) MX2024000986A (https=)
PY (1) PY2261702A (https=)
TW (1) TW202321210A (https=)
UY (1) UY39863A (https=)
WO (1) WO2023002409A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
AU2022306289A1 (en) 2021-07-09 2024-01-18 Aligos Therapeutics, Inc. Anti-viral compounds
JP7624093B2 (ja) 2022-04-08 2025-01-29 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2024031089A1 (en) 2022-08-05 2024-02-08 Gilead Sciences, Inc. Sars-cov2 main protease inhibitors
WO2025125695A2 (en) * 2024-12-17 2025-06-19 Medchemica Consultancy Ltd Chemical compoundsid50000167790940 p. doc 2025-05-07 filing no.:19

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1200825B (de) * 1962-01-13 1965-09-16 Hoechst Ag Verfahren zur Herstellung von 3, 5-Dioxo-triazolidinen
WO2010149755A1 (en) * 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17

Also Published As

Publication number Publication date
PY2261702A (es) 2023-06-14
TW202321210A (zh) 2023-06-01
KR20240038996A (ko) 2024-03-26
US20250092016A1 (en) 2025-03-20
UY39863A (es) 2023-02-28
EP4373814A1 (en) 2024-05-29
AU2022315058A1 (en) 2024-02-08
CA3226758A1 (en) 2023-01-26
WO2023002409A1 (en) 2023-01-26
JP2024527424A (ja) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2024000986A (es) Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus.
SA522433087B1 (ar) Sos1 مثبطات
MX2024000271A (es) Inhibidor de shp2 y uso del mismo.
JOP20200278B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
MX2021005012A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
MX2022013081A (es) Compuestos para el tratamiento de sars.
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2024015455A (es) Sales de inhibidores de homologo 1 del hijo de sevenless (sos1)
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
ECSP20082339A (es) Moduladores de la expresión de apol1
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
CL2021002176A1 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos (divisional de la solicitud n° 202002040)
MX2023013577A (es) Composiciones de bismuto-tiol y metodos de uso.
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
CL2022000214A1 (es) Inhibidores de enzimas
PE20200600A1 (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc
BR112022023187A2 (pt) Compostos para o tratamento da sars
JOP20220355A1 (ar) مثبطات rip1k
MX2024014262A (es) Inhibidores de parg